Johnson & Johnson - Search News

Johnson & Johnson's Spravato nasal spray okayed

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Fast Company on MSN · 1d

Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray,

U.S. News & World Report · 1d

FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants,

Bears hire Ben Johnson

USA Today · 1d

Ben Johnson introduced as Bears head coach: 'I wanted to stay in this division'

Ben Johnson expressed gratitude for his time with the Detroit Lions head coach, calling Dan Campbell a "friend" and "mentor" as he takes over Bears

Chicago Sun-Times · 1d

Bears landed Ben Johnson, who didn't want to be anywhere else

The Bears had targeted Johnson as their top candidate since firing head coach Matt Eberflus the day after Thanksgiving. They were convinced that his play-calling acumen and leadership skills were a perfect pairing with quarterback Caleb Williams and the rest of the Bears’ roster.

FOXSports on MSN · 2h

Bears coach Ben Johnson says his offense won't 'look the same as it did in Detroit'

New Bears HC Ben Johnson joined FS1's "Breakfast Ball" and "The Herd" to share what he might do to unlock Caleb Williams' potential.

10h

Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

17h

Johnson & Johnson: Hold Rating Amid Mixed Performance and Future Uncertainties

Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...

1hon MSN

Johnson & Johnson's SWOT analysis: oncology portfolio drives growth amid challenges

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

WTTW4h

Johnson Brushes Off Threat of Arrest for Failing to Help Trump’s Mass Deportation Effort

We are not going to be intimidated by those acts of terror to radically shift our way of living,” Mayor Brandon Johnson said. “That’s what individuals who stoke fear into people want to see happen.” ...

18h

Balanced Expectations Amid Challenges and Opportunities for Johnson & Johnson: Hold Rating Issued

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...

10hon MSN

Jim Cramer Likes Johnson & Johnson (JNJ) and the Kenvue Spin-Off – Here’s Why

We recently published a list of Jim Cramer Discusses TikTok Ban, President Trump & These 6 Stocks. In this article, we are ...

J&J Reports Strong Revenue and Profit but Faces Challenges in 2025

Johnson & Johnson reported better-than-expected quarterly revenue and profit on higher sales of cancer drugs and some medical devices. But shares slipped 3.2% to $143.35 in Wednesday morning trading, ...

16h

Johnson & Johnson price target lowered to $155 from $170 at Stifel

Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Johnson & Johnson's Spravato nasal spray okayed

Bears hire Ben Johnson

Related topics